![Medios AG (PK)](/common/images/company/NO_MEDOF.png)
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases Merck (NYSE:...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the Phase 3 KeyVibe-008 trial based on the recommendation of an independent Data...
Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sankyo and Merck to co-develop and co-commercialize...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the first patient has been dosed in the IDeate-Lung02 phase 3 trial...
Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11% KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding...
Opinion granted based on positive overall survival and progression-free survival results from the Phase 3 KEYNOTE-A39 trial Positive opinion marks step forward for a potential new first-line...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 13.64 | 13.64 | 13.64 | 2000 | 13.64 | CS |
52 | 0 | 0 | 13.64 | 13.64 | 13.64 | 2000 | 13.64 | CS |
156 | -36.36 | -72.72 | 50 | 50 | 13.64 | 1075 | 16.17674419 | CS |
260 | -28.3179 | -67.4912233453 | 41.9579 | 50 | 13.64 | 875 | 27.20801143 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.